The findings revealed that the semaglutide cohort had significantly lower odds of developing several complications over different time frames: Diabetic macular edema: 1-year odds ratio (OR) 0.52, 5-year OR 0.45, lifetime OR 0.42 Intravitreal anti-VEGF injections: 1-year OR 0.63, 5-year OR 0.55, lifetime OR 0.48 Vitreous hemorrhage: 1-year OR 0.37, 5-year OR 0.36, lifetime OR 0.31 Pars plana vitrectomy: 1-year OR 0.43, 5-year OR 0.41, lifetime OR 0.39 Pan retinal photocoagulation: 1-year OR 0.33, 5-year OR 0.32, lifetime OR 0.28 The study concluded that in patients with diabetic retinopathy, semaglutide use is associated with significantly lower odds of developing diabetic macular edema, vitreous hemorrhage, pars plana vitrectomy, pan retinal photocoagulation, and requiring intravitreal anti-VEGF injections
This is the universally accepted starting dose for semaglutide, whether compounded or brand-name
Critics, however, argue the conclusion is premature
Many people on these medications find that adding electrolyte beverages helps maintain hydration without the burden of plain water alone
